OCCURRENCE OF ADVERSE DRUG REACTIONS ASSOCIATED WITH HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY AT MBAGATHI DISTRICT HOSPITAL, NAIROBI, KENYA
|
|
- Amberly Wheeler
- 5 years ago
- Views:
Transcription
1 November 2011 Ea s t Af r i c a n Me d i c a l Jo u r n a l 363 East African Medical Journal Vol. 88 No. 11 November 2011 OCCURRENCE OF ADVERSE DRUG REACTIONS ASSOCIATED WITH HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY AT MBAGATHI DISTRICT HOSPITAL, NAIROBI, KENYA M. W. Wangai, MD, MPH, PhD, Deputy Chief of Party, Management Sciences for Health, P. O. Box , Nairobi, Kenya, M. A. Mwanthi, PhD, Head, Disease Prevention, Control and Health Promotion, Department of Community Health, College of Health Sciences, University of Nairobi, P. O. Box , Nairobi, G. G. Mbugua, MD, MPH, PhD, Public health specialist/chief Medical Research Officer, Centre for Microbiology Research, Kenya Medical Research Institute, P. O. Box , Nairobi, P. K. Wangai, MD, MPH, PhD, Medical Director, Medicare Wellness Centres, P. O. Box , Nairobi, Kenya, A. J. Suleh, MBChB, CTM, MMed (Int. Med), Consultant Physician and L. A. Kocholla, BDS, Msc, Dip HSM, Medical Superintendent, Mbagathi District Hospital, P. O. Box , Nairobi, Kenya Request for reprints to: Dr. M. W. Wangai, Deputy Chief of Party, Management Sciences for Health, P. O. Box , Nairobi, Kenya OCCURRENCE OF ADVERSE DRUG REACTIONS ASSOCIATED WITH HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY AT MBAGATHI DISTRICT HOSPITAL, NAIROBI, KENYA M. W. WANGAI, M. A MWANTHI, G. G. MBUGUA, P. K. WANGAI, A. J. SULEH and L. A. KOCHOLLA ABSTRACT Background: Life-saving highly active anti-retroviral therapy (HAART) has been accompanied by the challenge of incident adverse drug reactions (ADRs). Locally generated data is scanty, inadequately documented, and therefore not available to inform revision of clinical protocols. Objective: To study and document the magnitude and type of ADRs associated with HAART over a 42 month period at Mbagathi District Hospital (MDH) Nairobi. Design: A retrospective cohort study. Setting: A high burdened HIV comprehensive care clinic based at the Mbagathi District Hospital in Nairobi, Kenya. Subjects: HIV infected patients receiving highly active anti-retroviral therapy (HAART) Results: Adverse drug reactions associated with HAART occurred in 63% of adult study subjects. Majority (91.4%) of the ADRs experienced were medium to long term conditions, namely peripheral neuropathy in 33.3%, lipodystrophy in 32.6%, hepatic toxicity in 24.4% and lactic acidemia in 4.1 % of patients. Furthermore, occurrence of all the ADRs was associated with increasing baseline age (p<0.0001). Gender differences were found in patients with lipodystrophy (p<0.001), and lactic acidemia (p=0.047), with a female preponderance. Conclusion: Adverse drug reactions were experienced by 63% patients on HAART. Majority of the ADRs were those commonly associated with the medium to long term use of stavudine and nevirapine. Despite the high frequency of ADRs, patient outcomes were favourable as there were no reported deaths or hospitalisations. INTRODUCTION The past decade has seen the introduction of highly active anti-retroviral therapy (HAAR T) which has dramatically reduced morbidity and mortality from HIV - related complications and improved the quality of life among HIV infected patients worldwide (1). However, HAART has been associated with incident of adverse drug reactions (ADRs) (2). Adverse events are the key underlying factors to therapy change or non-adherence to medicines (3, 4). Patients with ADRs are nearly 13 times less likely to have % adherence and likely to experience three and a half times increased risk of virologic, immunologic and clinical failure. (5). The occurrence and magnitude of ADRs in developed countries is well documented, while this is not the case in developing countries. In this regard, locally generated data are required to improve clinical protocols and outcomes in Kenya. This study examined ADRs associated with HAART in adult study subjects and their possible risk factors over a 42 month period in a high burdened public health facility, the Mbagathi District Hospital, Nairobi.
2 364 Ea s t Af r i c a n Me d i c a l Jo u r n a l November 2011 MATERIALS AND METHODS This was a retrospective cohort study design. It examined the clinical encounters of patients managed at the MDH over a three and a half year period (from mid 2003 to the end of 2007). By December 2007, over 7,374 patients had registered to receive comprehensive HIV care and out of this number, 4,034 patients were on HAART. The HAART regimens used at the hospital complied with the Kenya National HAART Guidelines (6) that predominately utilise stavudine based regimens. Stratified random sampling proportional to size of the adult HAAR T population was used to select the study subjects. Data on bio-demographic, clinical and immunologic parameters, treatment regimens, duration of treatment to experiencing ADRs, types of ADRs experienced and the outcome of the ADRs were extracted from the study subjects medical records. These data were analysed using Statistical Package for Social Sciences (SPSS) TM version 12.0 for Windows. Descriptive statistics, chi-square test of statistic, bivariate comparisons of baseline continuous symmetric characteristics, linear mixed-effect models were used to characterise the experienced ADRs, establish change in continuous variables (such as CD4 counts, weight and age), and determine statistical associations and levels of significance. The analyses characterised the number and type of adverse reactions, computed odds ratios, and determined risk for occurrence of the ADRs and possible significant risk factors associated with ART. Ethical clearance was granted by the committees of Kenyatta National Hospital and College of Health Sciences, University of Nairobi and the Ministry of Science and Technology. RESULTS A total of 414 adult study subjects were sampled from 4,034 patients on HAART. These study subjects had a mean baseline age and weight of 34.1 years (standard deviation (sd)±7.84) and 57.9 Kg (sd ±10.6) respectively. Using random sampling with stratification by gender, the study subjects comprised 65.9% (272/413) female patients and 34.1 % (141/413) males. About 68.6% (179/261) of patients with ADRs were females, while 31.4% (82/261) were males patients. Despite this finding gender was not a significant risk factor in the occurrence of ADR, p=0.127 (Table 1). Sixty percent (154/259) of patients with ADRs had been commenced on D4T30/3TC/NVP (Table 1). The second highest (n= 69, 26.6%) number of patients with ADRs were patients on D4T40/3TC/ NVP. Seventy seven percent ( ) of patients with ADRs and commenced on D4T30/3TC/NVP were female while 22.73% (351154) were males. Among patients with ADRs started on D4T40/3TC/NVP, 60.87% (42/69) were females and 39.13% (27/69) were males. Similarly, the one female patient started on AZT based regimen also experienced an ADR. Eighty six percent (223/259) of patients with ADRs had been commenced on NVP based regimens while 13.9 % (36/259) were on EFV based regimens (Table 1). Among the females with ADRs, 91.2% ( ) were on NVP based regimens, while 8.8% (161181) were on EFV based regimens. Among the males with ADRs, % (62/82) of patients were on NVP based regimens while 24.39% (20/82) were on EFV based regimens. Table 1 Comparison of Existence of ADRs with Patient Bio-Demographic and Immunological Factors Patients who had ADRs P values Total no. % No no. (%) Yes no. (%) Gender N=413 - Male 141(34.14) 59(38.82) 82(31.42) Referent - Female 272(65.86) 93(61.18) 179(68.58) Marital status N=410 - Married 189(46.10) 72(47.37) 117(45.35) Referent - Single 110(26.83) 41(26.97) 69(26.74) Widowed 69(16.83) 20(13.16) 49(19.0) Divorced 42(10.24) 19(12.50) 23(8.91) WHO stage N=412 Stage 1 and 2 39(9.47) 13(8.55) 26(10.00) Referent Stage 3 325(78.88) 123(80.92) 202(77.69) Stage 4 48(11.65) 16(10.53) 32(12.31) ART regimen at baseline N=410 D4 T30/3 TC/NVP 240(58.25) 86(56.21) 154(59.46) Referent D4 T30/3 TC/EFV 43(10.44) 15(9.80) 28(10.81) D4 T 40/3 TC/NVP 116(28.16) 47(30.72) 69(26.64) D4 T40/3 TC/EFV 13(3.16) 5(3.27) 8(3.09) 0.894
3 November 2011 Ea s t Af r i c a n Me d i c a l Jo u r n a l 365 Types of Adverse Drug Reactions: Sixty three percent (95% CI %), of patients experienced one or more ADRs during the study period (Table 2). Exactly, 64.4% (168/261) of study subjects who manifested a reaction had one ADR, 26.5% (69/261) had two, while 9.3% (24/261) had three different types of ADRs within the study period. When all the ADRs were considered collectively, binary logistic regression model revealed significant correlation between occurrence and increasing baseline age (p<0.0001) but not with baseline CD4 cell counts (p=0.944). For every additional year at baseline, the probability of experiencing an ADR increased by 7.6 % (OR 1.076, 95% CI , p< ). Hepatic toxicity, lipodystrophy, lactic acidosis and peripheral neuropathy were the key medium to long term adverse reactions experienced by patients in the study period. They collectively comprised 91.4% (391/428) of all the incidents of ADRs and had an incidence rate of 49% per 100 person years. About 33% of patients (n=138, 95% CI %) had peripheral neuropathy, while lipodystrophy occurred in 32.6% (n=135, 95% CI %) and hepatic toxicity in 24.4% (n=l 01, 95% CI %) and lactic acidemia in 4.1 % (n=17, 95% CI 2.19, 6.03) of patients. Approximately, 13% (42/335) of patients experienced severe forms of these ADRs. Lipodystrophy and lactic acidemia were the only two adverse reactions where the female patients were significantly more affected than their male counterparts (p<0.001 and p=0.047 respectively). Seventy nine percent ( ) of female patients experienced lipodystrophy compared to 20.7% (28/135) of male patients. Exactly, 88.2% (15117) of female patients and 11.8 % (2117) of male patients experienced lactic acidemia (Table 2). Factors associated with the medium to long term ADRs: When the data were adjusted for ARV regimens, bio-demographic factors, immunologic status and ADRs, there were no significant associations found between the occurrence of these ADRs with baseline weight, age and gender. Irrespective of the baseline regimen, data analysis showed slightly increased risk of experiencing the ADRs associated with increasing baseline CD4 cell count, HR (95% CI , p=0.011). After adjusting for bio-demographic factors, immunological and NRTI based regimens, single unmarried patients had a reduced risk of experiencing these ADRs (Hazard Ratio (HR) 0.66, 95% CI ) compared to divorced patients, p= When the risk for these ADRs was assessed in patients on D4T and AZT as compared to other NRTIs, namely TDF and ABC, patients on D4T had a higher risk by 4.4 times (HR 4.42,95% CI , p<0.0001). On other hand, those on AZT based regimens had a 2.1 times higher risk of experiencing one of these ADRs (HR 2.11,95% CI ; p<0.0001). The risk of having any of these ADRs was also explored among patients on EFV, NVP and Lopinavirlritonavir (LPV/r) based regimens. The risk of developing these ADRs in patients on EFV based regimens compared to those on LPV/r was less by 86% (HR 0.14, 95% CI, ; p<0.0001), while the risk of ADR in among those using NVP based regimens was less by 46.6% compared with those on LPV/r (HR 0.53,95% CI ; p=0.001). DISCUSSION The HIV infection is one of the specific factors that increase the risk of general adverse drug reactions Table 2 Types of ADRs in Adult HAART Patients by Gender (n=261) Occurrence of Mean baseline CD4 Female n Male p- ADRs n (%) 95% CI cell count (95%CI) (%) N(%) value or (sd) Overall (120.1,141.9) (63.04) (68.58) (31.42) Anemia 3(0.72) (sd±128.57) 2(66.67) 1(33.33) CNS symptoms 3(0.72) (sd±148.35) 1(33.33) 2(66.67) GIT symptoms 7(1.69) 97.83(22.02,173.6) 5(71.43) 2(28.57) Hepatic , 120.4(103.2,137.6) 65(64.36) 36(35.64) toxicity (24.40) , 107 Lipodystrophy 130.2(115.5,145.0) (79.26) 28(20.74) <0.001 (32.61) Muscle pain 7(1.69) (40.7,178.7) 4(57.14) 3(42.86) 0.25 Peripheral , 125.3(110.4,140.3) 90(65.22) 48(34.78) neuropathy (33.33) Skin Reactions 15(3.62) 1.82, (122.8,221.8) 7(46.67) 8(55.33) Lactic acidemia 17(4.11) 2.19, (77.2,158.6) 15(88.24) 2(11.76) Others 2(0.48) (sd±45.25) 0(0) 2(100.0)
4 366 Ea s t Af r i c a n Me d i c a l Jo u r n a l November 2011 (7). Among the MDH adult HIV study subjects, 63% HIV positive study subjects on HAART experienced ADRs. Nearly (90%) all the HAART patients were commenced on D4T based regimens as per the national treatment guidelines that were in effect at the time of the study period. Types of adverse drug reactions: A few of the more persistent or severe short term ADRs were recorded. The type of short term ADRS and the proportion of the affected areas of the body were as follows: central nervous system symptoms (0.7%), skin hypersensitivity rashes (3.6%), myopathy (1.5%), GIT symptoms (1.5%). As in other similar studies where D4T based regimens are predominantly used, the most common ADRs recorded were peripheral neuropathy (33%), lipodystrophy (33%), hepatic toxicity (24.4%) and lactic acidemia (4.1 %) (8-11). These are known toxicities of NR TIs over the medium to long-term and thought to be secondary to inhibition of mitochondrial DNA polymerase b (9). The four ADRs comprised 91.4% of all the incident ADR reactions and had an incidence rate of 49% per 100 person years. Factors associated with medium to long term ADRs: Increasing age was the only bio-demographic factor found to be associated with occurrence of ADRs. For every additional year at baseline, the probability of experiencing medium to long term ADR increased 7.6%. This is consistent with literature and is possibly due to age-related alteration in pharmacokinetics and pharmacodynamics (12). Occurrence of ADRs was independent of gender, marital status, baseline CD4 cell count. The female gender was not a significant risk factor to occurrence of ADRs collectively (p=0.127). This finding concurred with studies conducted by Johnson et al (13). More specifically, Menezes de Padua et al showed that there is a two-fold heightened ADR risk among the female gender to short term reactions that occurred before the fourth month of HAART, such as GI symptoms and allergy (14). This study demonstrated that occurrence of lipodystrophy (p<0.001) and lactic acidemia (p=0.047) were associated with the female gender. Similarly, Bonfanti et al demonstrated increased risk of lipodystrophy among the females (15). Furthermore, the higher risk of lactic acidosis in the female gender was demonstrated by Bonnet et al, Geddes et al and Boulassel et al (16-18). The increased propensity for NR TI -related adverse events in women may be related to higher levels of intercellular phosphorylation (19). This study demonstrates that adult HIV positive patients on D4T and AZT based regimens had increased risk of experiencing ADRs compared to their counterparts on TDF or ABC based regimens by four and two times respectively. TDF is a much safer medicine than either D4T or AZT (20). This has been replicated in several settings and has led to recent guideline changes for HAART management internationally (20). The risk of ADRs in adult HIV positive patients on EFV based regimens was less by 86% compared to patients on LPV/r based regimens (HR 0.14,95% CI, ; p<0.0001). While the risk of ADR in those using NVP based regimens was less by 46.6% than for those on LPV/r (HR 0.53,95% CI ; p=0.001). Based on these results, it appears as if EFV and NVP are safer than LPV/r. However, the patients on LPV/r were more likely to have been on HAART for longer and most probably were switched from NVP or EFV at one point in time. Additional study with adjustments for length of time on the individual ARVs may be needed to determine the true correlation between these medicines and risk of ADRs. Despite the high frequency of ADRs among patients on HAART, the outcomes were favourable as there were no documented incidences of deaths or hospitalisations. In addition, a proportion of patients (44-59%) with medium to long term ADRs already had resolution of their reactions by end of the study period. Limitations: First, this was a retrospective cohort study using routinely collected clinical data without independent real time confirmation of existence of adverse events or their outcome. However, this was minimised with the use of standardised patient clinical encounter forms based on the national protocols, designed to systematically collect information from clinical encounters. Non naive patients were also excluded from the study, because of increased likelihood of non availability of initial data. Second, the ADRs documented in patient records were based on the clinical acumen of the clinicians, without independent laboratory and radiological confirmation of the existence of the event in the majority of cases. Variability was minimised by the use of standardised validated protocols. Lipodystrophy was the only ADR that would need additional case definition and validation to describe severity of the event. This has not yet been done by the world medical fraternity. Third, it was not possible to study other factors, for lack of sufficient data, that could influence the occurrence of ADRs such as viral hepatitis, renal insufficiency, and alcohol consumption. Despite these limitations and considering that this was a baseline study among the MDH HAART cohort, it is we believed that the findings are suitable and valid for informing programme and clinical management and comparing with other national, regional and global HAAR T cohorts studies. In conclusion the ADRs that occurred frequently among HAART patients and were largely associated
5 November 2011 Ea s t Af r i c a n Me d i c a l Jo u r n a l 367 with the medium to long term use of stavudine and nevirapine. Over a follow-up period of three and a half years approximately 63% of HIV infected patients on HAART presented with an ADR. Patients on D4T and AZT were significantly at higher risk of experiencing ADRs than their counterparts on TDF and ABC. In addition, increasing age at initiation of therapy was found to be the only bio-demographic risk factor. Despite the high frequency of ADRs there were no reported deaths or hospitalisations. ACKNOWLEDGEMENTS The HAART patients, Management and Staff of Mbagathi District Hospital and MSF-B, whose valuable support and cooperation made this research possible. The late Dr Rosemary Nguti PhD (Bio- Statistics), Former Lecturer, School of Mathematics, University of Nairobi who gave extremely valuable guidance, support on the data analysis and statistical review of the study. Dr. Elizabeth Bukusi MMed.(OB/ GYN, MPH, PhD) for reviewing the original PhD thesis from which this paper was drawn. REFERENCES 1. Palella F. J. Jr., Delaney K. M., Moorman A. C., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Eng. J. Med. 1998; 338: The AIDS Education and Training Centers National Resource Center. Clinical Manual for Management of the HIV-Infected: Section 4; Complications of Antiretroviral Therapy Adverse Reactions to HIV medications. Adult Edition. aetc/pdf/aetc-cm_ pdf 2006 accessed 20th March Hira, S., Heywood, P., Gold, J., et al. HIV/AIDS treatment and prevention in India: modeling the cost and consequences. The World Bank Washington, DC. 2004; World Health Organization Managing Anti-retroviral Side effects: A Practical Guide HIV Anti-retroviral Newsletter. Issue 10, December 2003, Manila: WHO Regional Office for the Western Pacific. 5. Ickovics, J. R., Cameron, A., Zackin, R., et al. Consequences and determinants of adherence to antiretroviral medication: results from Adult AIDS Clinical Trials Group protocol 370. Antivir. Ther. 2002; 7: Guidelines for Anti-retroviral Drug Therapy in Kenya. 3rd Edition. National AIDS and STI Control Program. Ministry of Health (MOH), Republic of Kenya Barranco P, Lopez-Serrano M.C. General and epidemiological aspects of allergic drug reactions. Clin. Exp. Allergy. 1998; 28 (supp14): Carr, A. and Cooper, D. A. Adverse effects of antiretroviral therapy. Lancet 2000; 356: Walker, U. A. and Brinkman, K. NRTI induced mitochondrial toxicity as a mechanism for HAART related lipodystrophy: fact of fiction? HIV medicine. 2001; 2: Spacek, L., Shihab, H., Kamya, R., et al. Response to anti-retroviral therapy in HIV infected patients attending a public, urban clinic in Kampala, Uganda. Clin. Infec. Dis. 2006; 42: Coetzee, O., Hildebrand, K., Boulle, A., et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa, AIDS 2004; 18: Ramesh, M., Pandit, J. and Parthasarathi, G. Adverse drug reactions in a south Indian hospital their severity and cost involved. Pharmacoepidemiol Drug. Saf. 2003; 12: Johnson, M. O., Charlesbois, E., Morin, S. F., et al. Perceived Adverse Effects of Anti-retroviral Therapy. J. Pain and Sympt. Manag. 2005; 29: Menezes de Padua, C. A., Cesar, C. C., Bonolo, P. F., et al. High incidence of adverse reactions to initial anti-retroviral therapy in Brazil. Braz. J. Med. Biol. Rec. 2006; 39: Bonfanti, P., Gulisano, C., Ricci, E., et al. Risk factors for lipodystrophy in the CISAI cohort. Biomed. Pharmacotherapy. 2003; 57: Bonnet, et al. Risk Factors for lactic acidosis in HIV -infected patients treated with nucleoside reverse transcriptase inhibitors: a case control study. Clinic. Infect. Dis. 2003; 36: Geddes, R., Knight, S., Moosa, M. Y., et al. A high incidence of nucleoside reverse transcriptase inhibitor (NR TI)-induced lactic acidosis in HIV -infected patients in a South African context. S. Afr. Med. J. 2006; 96: Boulassel, M. R., Morales, R., Murphy, T., et al. Gender and long-term metabolic toxicities from antiretroviral therapy in HIV-l infected persons. J. Med. Virol. 2006; 78: Currier, L. S., Spino, C., Grimes, J. et al. Differences between women and men in adverse events and CD4+ responses to nucleoside analogue therapy for HIV infection. J. Acquir. Immune. Defic. Sydr. 2000; 24: Bartlett, J. G., Gallant, J. E. eds Medical Management of HIV Infection: Edition. Johns Hopkins Medicine Health Publishing Business Group, Baltimore, Maryland USA 2005.
HIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationTHE PATTERN OF HEARING DISORDERS IN HIV POSITIVE PATIENTS ON ANTI - RETROVIRALS AT KENYATTA NATIONAL HOSPITAL
October 2010 Ea s t Af r i c a n Me d i c a l Jo u r n a l 425 East African Medical Journal Vol. 87 No. 10 October 2010 THE PATTERN OF HEARING DISORDERS IN HIV POSITIVE PATIENTS ON ANTI - RETROVIRALS AT
More informationPharmacovigilance of highly active antiretroviral therapy among adult patients in a large urban HIV treatment center in Nigeria
Abstract no. A-641-0120-07827 Pharmacovigilance of highly active antiretroviral therapy among adult patients in a large urban HIV treatment center in Nigeria I.O. Abah 1, P. Ugoagwu, V. Ojeh, L. Ogwuche,
More informationTreatment strategies for the developing world
David A Cooper National Centre in HIV Epidemiology and Clinical Research The University of New South Wales Sydney, Australia First line standard of care First line in the developing world First line failure
More informationInt. J. Pharm. Sci. Rev. Res., 26(2), May Jun 2014; Article No. 15, Pages: 79-83
Research Article Comparing Efficacy and Safety of Stavudine Plus Lamivudine Versus Zidovudine Plus Lamivudine in Combination with Nevirapine in HIV Infected Individuals Receiving Antiretroviral Therapy
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationInt. J. Adv. Res. Biol. Sci. (2017). 4(8): 28-35
Int. J. Adv. Res. Biol. Sci. (1). (8): 835 International Journal of Advanced Research in Biological Sciences ISSN: 38869 www.ijarbs.com DOI: 1.19/ijarbs Coden: IJARQG(USA) Volume, Issue 8 1 Research Article
More informationReasons for Anti-Retroviral Regimen Changes in HIV/AIDS patients of Ayder Referral Hospital ART clinic, Mekelle, Ethiopia.
Reasons for Anti-Retroviral Regimen Changes in HIV/AIDS patients of Ayder Referral Hospital ART clinic, Mekelle, Ethiopia. LEMLEM GEBREMEDHIN *, AMANUEL BIRHANE 2, 2 Pharmacology and Toxicology course
More information3 East and Central African Journal of Pharmaceutical Sciences Vol. 16 (2013) 3-12
3 East and Central African Journal of Pharmaceutical Sciences Vol. 16 (2013) 3-12 Detection and Management of Adverse Drug Reactions Related to Antiretroviral Drugs among HIV/AIDS Patients in Kiambu Sub-County,
More informationTHE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2010
THE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2010 The South African Antiretroviral Treatment Guidelines 2010 Goals of the programme Achieve best health outcomes in the most cost-efficient manner
More informationADVERSE DRUG REACTIONS AMONG HIV INFECTED AND UNINFECTED ADULTS RECEIVING ANTi-TUBERCULOUS THERAPY AT KENYATTA NATIONAL HOSPITAL
October 2011 Ea s t Af r i c a n Me d i c a l Jo u r n a l 327 East African Medical Journal Vol. 88 No. 10 October 2011 ADVERSE DRUG REACTIONS AMONG HIV INFECTED AND UNINFECTED ADULTS RECEIVING ANTI- TUBERCULOUS
More informationTreatment experience in South Africa. Dr Ian Sanne Clinical HIV Research Unit University of the Witwatersrand
Treatment experience in South Africa Dr Ian Sanne Clinical HIV Research Unit University of the Witwatersrand Overview South African Prevalence Adherence Combination ddi + d4t Nevirapine Hepatotoxicity
More informationMetabolic complications of HIV and HAART: The hyperlactataemia syndromes
Metabolic complications of HIV and HAART: The hyperlactataemia syndromes Colin Menezes Division of Infectious Diseases Department of Internal Medicine Chris Hani Baragwanath Academic Hospital University
More informationFixed Dose Combination a Simplified Approach to Pediatric Antiretroviral Treatment
Fixed Dose Combination a Simplified Approach to Pediatric Antiretroviral Treatment Dr. David Pugatch Clinton Foundation Phnom Penh, Cambodia February, 2007 Lecture Goals To introduce and define fixed dose
More informationANTIRETROVIRAL THERAPY IN NAMIBIA
ANTIRETROVIRAL THERAPY IN NAMIBIA SAHIVCS CONFERENCE CAPETOWN 25-28- NOVEMBER 2012 DR. F. MUGALA MUKUNGU M.MED (INT.MED) SPECIALIST PHYSICIAN KATUTURA STATE HOSPITAL WINDHOEK NAMIBIA Current status in
More informationChallenges in the management of treatment-experienced patients in Sub- Saharan Africa: Clinical Perspective
Challenges in the management of treatment-experienced patients in Sub- Saharan Africa: Clinical Perspective Dr. Patricia Aladi Agaba Senior Lecturer, Department of Family Medicine, University of Jos Honorary
More informationGENERAL PROFILE AND SURVIVAL PROBABILITIES OF HIV PATIENTS REGISTERED AT ANTI RETROVIRAL THERAPY CENTRE, NEW CIVIL HOSPITAL, SURAT, GUJARAT
Original article GENERAL PROFILE AND SURVIVAL PROBABILITIES OF HIV PATIENTS REGISTERED AT ANTI RETROVIRAL THERAPY CENTRE, NEW CIVIL HOSPITAL, SURAT, GUJARAT Sridhar P Ryavanki 1, J K Kosambiya 2, Alap
More informationFirst line ART Rilpirivine A New NNRTI. Chris Jack Physician, Durdoc Centre ethekwini
First line ART Rilpirivine A New NNRTI Chris Jack Physician, Durdoc Centre ethekwini Overview: Rilpirivine an option for ARV Naïve patients History Current guidelines Efficacy and Safety Tolerability /
More informationSupplemental Digital Content 1. Combination antiretroviral therapy regimens utilized in each study
Supplemental Digital Content 1. Combination antiretroviral therapy regimens utilized in each study Study Almeida 2011 Auld 2011 Bassett 2012 Bastard 2012 Boulle 2008 (a) Boulle 2008 (b) Boulle 2010 Breen
More informationSHOULD A TRIAL EVALUATING THE USE OF LOW DOSE STAVUDINE BE CONDUCTED?
SHOULD A TRIAL EVALUATING THE USE OF LOW DOSE STAVUDINE BE CONDUCTED? ETHICAL, CLINICAL AND COMMUNITY CONSIDERATIONS Eric Goemaere, MD, DTMH, PHD Senior HIV/TB program adviser MSF South Africa We loved
More informationSA HIV Clinicians Society Adult ART guidelines
SA HIV Clinicians Society Adult ART guidelines In draft format Graeme Meintjes (on behalf of the guidelines committee) Selected topics When to start ART First-line Second-line Third-line Patients with
More informationARV pharmacovigilance: moving
ARV pharmacovigilance: moving beyond spontaneous reporting Karen Cohen Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Outline Limitations of ADR
More informationOptimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents
Optimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents Victor Musiime, MBChB, MMED, PhD Senior Lecturer, Makerere University Investigator, Joint Clinical Research Centre (JCRC)
More informationAntiretroviral treatment outcomes after the introduction of tenofovir in the public-sector in South Africa
Antiretroviral treatment outcomes after the introduction of tenofovir in the public-sector in South Africa Alana T Brennan, Kate Shearer, Mhairi Maskew, Prudence Ive, Ian Sanne, Matthew P Fox Health Economics
More informationPRIORITIES FOR HIV/AIDS PROCUREMENT AND PRODUCT DEVELOPMENT
PRIORITIES FOR HIV/AIDS PROCUREMENT AND PRODUCT DEVELOPMENT Dr Chewe Luo MMed (Paeds), Mtrop Paed, PhD Senior Adviser and Team Leader Country Programme Scale up HIV Section Programme Division UNICEF, NY
More informationPAEDIATRIC HIV INFECTION. Dr Ashendri Pillay Paediatric Infectious Diseases Specialist
PAEDIATRIC HIV INFECTION Dr Ashendri Pillay Paediatric Infectious Diseases Specialist Paediatric HIV Infection Epidemiology Immuno-pathogenesis Antiretroviral therapy Transmission Diagnostics Clinical
More informationDescription of d4t toxicities among 3 OI/ART clinics patients on ARV in Cambodia
Description of d4t toxicities among 3 OI/ART clinics patients on ARV in Cambodia First Phnom Penh Symposium on HIV Medicine Dr. Khim Sam Ath, MSF Belgium Introduction Scale up of access to HAART has become
More informationModule 6: ARVs in Children
Module 6: ARVs in Children Module Objectives To review the use of ARVs in children and their impact on disease progression To provide nurses with a general understanding of the differences in ARV use in
More informationThe relationship between adherence to clinic appointments and year-one mortality for HIV infected patients at a Referral Hospital in Western Kenya
The relationship between adherence to clinic appointments and year-one mortality for HIV infected patients at a Referral Hospital in Western Kenya Muthusi, K; Burmen, B 8th International Workshop on HIV
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationHIV long term complications
HIV- 2015 long term complications 4th Asian Conference on Hepatitis & AIDS 22-23 May 2015, Xi'an, China Kees Brinkman Amsterdam The Netherlands NL 2012: known 17.000 (0,1%) treatment 85% (all) China 2011:
More informationWHO MODEL LIST OF ESSENTIAL MEDICINES APPLICATION. stavudine/lamivudine/nevirapine fixed-dose combination tablets for the treatment of HIV-1 infection
WHO MODEL LIST OF ESSENTIAL MEDICINES APPLICATION stavudine/lamivudine/nevirapine fixed-dose combination tablets for the treatment of HIV-1 infection 1. Summary statement of proposal for inclusion, change,
More informationGender Differences in clinical and immunological outcomes in South African HIV-infected patients on HAART
RESEARCH REPORT TITLE Gender Differences in clinical and immunological outcomes in South African HIV-infected patients on HAART Submitted for the degree: MSc (MED) EPIDEMIOLOGY AND BIOSTATISTICS School
More informationAbiyie Zeleke. Department of Pediatrics and Child Health, Debre Markos University, Debre Markos, Ethiopia.
Vol. 8(11), pp. 125-132, November 2016 DOI: 10.5897/IJMMS2015.1164 Article Number: 9CC1DA261337 ISSN 2006-9723 Copyright 2016 Author(s) retain the copyright of this article http://www.academicjournals.org/ijmms
More informationthyroid FUNCTION among hiv/aids patients on highly active
474 Ea s t Af r i c a n Me d i c a l Jo u r n a l December 2010 East African Medical Journal Vol. 87 No. 12 December 2010 thyroid FUNCTION among hiv/aids patients on highly active anti-retroviral therapy
More informationGlobal AIDS New Developments in Care
Global AIDS New Developments in Care Royce C. Lin, MD Assistant Clinical Professor of Medicine scope pledge delivery future Adults and children estimated to be living with HIV, 2005 Western & Eastern Europe
More informationEbrahim Bera Department of Obstetrics & Gynaecology Rahima Moosa Mother-and-Child Hospital Wits University 28 November 2012
Ebrahim Bera Department of Obstetrics & Gynaecology Rahima Moosa Mother-and-Child Hospital Wits University 28 November 2012 Euphoria around survival from HIV 1.9 million people in SA now on ART New HIV
More informationWESTERN CAPE ART GUIDELINES PRESENTATION 2013
WESTERN CAPE ART GUIDELINES PRESENTATION 2013 The WC guidelines are based on SA National ART guidelines dated 24th March 2013 Acknowledgement goes to members of the Adult and Paediatric HAST policy advisory
More informationTOXICITY, TOLERABILITY, AND ADHERENCE TO THERAPY
SAFETY AND TOLERABILITY OF CURRENTLY AVAILABLE ANTIRETROVIRAL AGENTS * Esteban Martinez, MD, PhD ABSTRACT Safety and tolerability are important factors to consider when instituting or modifying therapy
More informationA Genetic Test to Screen for Abacavir Hypersensitivity Reactions
The Future of Pharmacogenetics in HIV Clinical Care A Genetic Test to Screen for Abacavir Hypersensitivity Reactions Evan Collins & Misty Bath CANAC/ACIIS 15 th Annual Conference Vancouver, BC April 2007
More informationA Descriptive Study of Outcomes of Interventions to Prevent Mother to Child Transmission of HIV in Lusaka, Zambia
ORIGINAL PAPER A Descriptive Study of Outcomes of Interventions to Prevent Mother to Child Transmission of HIV in Lusaka, Zambia Chibesa Shichitamba W, National Malaria Control Centre, Lusaka-Zambia ABSTRACT
More informationWhat are the most promising opportunities for dose optimisation?
What are the most promising opportunities for dose optimisation? Andrew Hill Liverpool University, UK Global Financial Crisis How can we afford to treat 15-30 million people with HIV in the future? Lowering
More informationAdult Guidelines. Sipho Dlamini. Division of Infectious Diseases & HIV Medicine University of Cape Town Groote Schuur Hospital
Adult Guidelines Sipho Dlamini Division of Infectious Diseases & HIV Medicine University of Cape Town Groote Schuur Hospital Cape Town CME 3 rd June 2017 Sports Science Institute, Newlands Outline of talk
More information2009 Recommendations for Antiretroviral Therapy in Adults and Adolescents. When to Start and What ART to Use in 1 st and 2 nd Line December 2009
2009 Recommendations for Antiretroviral Therapy in Adults and Adolescents When to Start and What ART to Use in 1 st and 2 nd Line December 2009 Historic Evolution of CD4 Criteria for ART Initiation in
More informationStructured Treatment Interruption in HIV Positive Patients. Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007
Structured Treatment Interruption in HIV Positive Patients Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007 Objectives To become re-acquainted with the basics of HAART for HIV infection
More informationUpdates on Revised Antiretroviral Treatment Guidelines Overview 27 March 2013
Updates on Revised Antiretroviral Treatment Guidelines 2013 Overview 27 March 2013 Introduction of Fixed Dose combination (FDC) FDCs will be available in facilities on 1 April 2013 The FDC ARV that will
More informationFurther publications can be obtained from the HIV/AIDS Unit, Department of Communicable Diseases, World Health Organization, Regional Office for
Further publications can be obtained from the HIV/AIDS Unit, Department of Communicable Diseases, World Health Organization, Regional Office for South-East Asia, World Health House, Indraprastha Estate,
More informationTDF containing ART: Efficacy and Safety. Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia
TDF containing ART: Efficacy and Safety Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia 1 Indications Treatment of HIV-1 in combination with other antiretroviral
More informationBHIVA Clinical Audit. Management of patients who switch therapy; re-audit of patients starting therapy from naïve
BHIVA Clinical Audit Management of patients who switch therapy; re-audit of patients starting therapy from naïve 1 2004-5 5 audit projects Reporting now:! Survey and case note review of patients switching
More informationTRANSITION TO NEW ANTIRETROVIRALS IN HIV PROGRAMMES
POLICY BRIEF HIV TREATMENT TRANSITION TO NEW ANTIRETROVIRALS IN HIV PROGRAMMES JULY 2017 WHO This policy brief provides advice on a phased approach to transitioning to new WHO-recommended HIV treatment
More informationPediatric Antiretroviral Resistance Challenges
Pediatric Antiretroviral Resistance Challenges Thanyawee Puthanakit, MD The HIVNAT, Thai Red Cross AIDS research Center The Research Institute for Health Science, Chiang Mai University Outline The burden
More informationDate of study period: April 12 May 7, 2010 and August September, 2010
Classification of antiretroviral therapy failure using immunologic and clinical versus virologic monitoring in HIV-infected children and adolescents in Cambodia Date of study period: April 12 May 7, 2010
More informationART TREATMENT PROGRAMME 2004
Presentation title ART TREATMENT PROGRAMME 2004 Cabinet decision in 29 th November 2003 Initial sites were hospital based, required central review National Costing Model of HIV/AIDS Treatment 2010 Cost
More informationClinical Case Scenario. HIVeEducation Workshop, Sint Maarten 2009
Clinical Case Scenario HIVeEducation Workshop, Sint Maarten 2009 Background Mrs. S is a 34 year-old woman who was referred from the VCT center after testing HIV positive three weeks ago. Her husband recently
More informationA STUDY TO EXPLORE THE IMPACT OF SOCIO- DEMOGRAPHIC FACTORS ON THE RESPONSE TO ANTIRETROVIRAL THERAPY IN GAUTENG DEPARTMENT OF HEALTH HELLEN MAJURU
A STUDY TO EXPLORE THE IMPACT OF SOCIO- DEMOGRAPHIC FACTORS ON THE RESPONSE TO ANTIRETROVIRAL THERAPY IN GAUTENG DEPARTMENT OF HEALTH BY HELLEN MAJURU A research report submitted to the Faculty of Health
More informationAssessment of the therapeutic success of antiretroviral combinations used in a HIV treatment center, Jos, Nigeria
World Journal of Pharmaceutical Sciences ISSN (Print): 3-330; ISSN (Online): 3-3086 Published by Atom and Cell Publishers All Rights Reserved Available online at: http://www.wjpsonline.org/ Original Article
More informationIntroduction: WHO recommends that criteria for starting ART be defined in national protocols and that these
ISSN: 0975-766X Available Online through Research Article www.ijptonline.com HEALTH PROFILE OF HIV POSITIVE INDIVIDUALS AT ANTI RETROVIRAL TREATMENT CENTRE, KADAPA DISTRICT Dr.K.Chandra Sekhar *, Dr. K.J.Kishore
More informationScottish Medicines Consortium
Scottish Medicines Consortium raltegravir, 400mg film-coated tablet (Isentress) No. (461/08) Merck, Sharp and Dohme Limited 04 April 2008 The Scottish Medicines Consortium has completed its assessment
More informationDNA Genotyping in HIV Infection
Frontier AIDS Education and Training Center DNA Genotyping in HIV Infection Steven C. Johnson M.D. Director, University of Colorado HIV/AIDS Clinical Program; Professor of Medicine, Division of Infectious
More informationDTG Versus LPV/r in Second Line (DAWNING): Outcomes by WHO- Recommended NRTI Backbone
DTG Versus LPV/r in Second Line (DAWNING): Outcomes by WHO- Recommended NRTI Backbone Aboud M, 1 Brites C, 2 Lu H, 3 Supparatpinyo K, 4 Hercilla L, 5 Sievers J, 1 Nascimento MC, 1 Hopking J, 6 Underwood
More information0% 0% 0% Parasite. 2. RNA-virus. RNA-virus
HIV/AIDS and Treatment Manado, Indonesia 16 november HIV [e] EDUCATION HIV is a 1. DNA-virus 2. RNA-virus 3. Parasite 0% 0% 0% DNA-virus RNA-virus Parasite HIV HIV is a RNA-virus. HIV is an RNA virus which
More informationAnumber of clinical trials have demonstrated
IMPROVING THE UTILITY OF PHENOTYPE RESISTANCE ASSAYS: NEW CUT-POINTS AND INTERPRETATION * Richard Haubrich, MD ABSTRACT The interpretation of a phenotype assay is determined by the cut-point, which defines
More informationFrailty and age are independently associated with patterns of HIV antiretroviral use in a clinical setting. Giovanni Guaraldi
Frailty and age are independently associated with patterns of HIV antiretroviral use in a clinical setting Giovanni Guaraldi Potential conflicts of interest Research funding: Jansen, Gilead, MSD, BMS Consultancies:
More informationTREATMENT OUTCOMES OF SECOND LINE ANTIRETROVIRAL THERAPY IN MBAGATHI DISTRICT HOSPITAL COMPREHENSIVE CARE CLINIC
TREATMENT OUTCOMES OF SECOND LINE ANTIRETROVIRAL THERAPY IN MBAGATHI DISTRICT HOSPITAL COMPREHENSIVE CARE CLINIC PRINCIPAL INVESTIGATOR: STEPHEN NDOLO KIIO REGISTRATION NUMBER: H58/63681/2010 A DISSERTATION
More informationWhat's new in the WHO ART guidelines How did markets react?
WHO 2013 ARV Guidelines What's new in the WHO ART guidelines How did markets react? Dr. J. Perriëns Coordinator, HIV Technology and Commodities HIV department, WHO, Geneva When to start in adults Starting
More information0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920
0.14 UNAIDS 0.053% 2 250 60 10% 94 73 20 73-94/6 8,920 12 43 Public Health Service Task Force Recommendations 5-10% for Use of Antiretroviral Drugs in 10-20% Pregnant HIV-1-Infected Women for Maternal
More information1. Africa Centre for Health and Population Studies 2. London School of Hygiene and Tropical Medicine 3. University College London
A systematic review of the effects of interrupted antiretroviral interventions for prevention of mother-to-child transmission of HIV on maternal disease progression and survival Naidu KK 1, Mori R 2, Newell
More informationFurther publications can be obtained from the HIV/AIDS Unit, Department of Communicable Diseases, World Health Organization, Regional Office for
Further publications can be obtained from the HIV/AIDS Unit, Department of Communicable Diseases, World Health Organization, Regional Office for South-East Asia, World Health House, Indraprastha Estate,
More informationSomnuek Sungkanuparph, M.D.
HIV Drug Resistance Somnuek Sungkanuparph, M.D. Associate Professor Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Adjunct Professor
More informationProspective study of Lopinavir based ART for HIV Infected ChildreN Globally (LIVING study): Interim 48-week effectiveness and safety results.
Prospective study of Lopinavir based ART for HIV Infected ChildreN Globally (LIVING study): Interim 48-week effectiveness and safety results. Victor Musiime, MBChB, MMED, PhD Senior Lecturer, Makerere
More informationClinical Management Guidelines 2012
Central American Course Monitoring and Evaluation for HIV/AIDS Policy and Program Management 1 2 3 4 Module 1 Unit 1 Clinical Management Guidelines 2012 National TB, HIV/AIDS & other STIs Programme Ministry
More informationEvolving Realities of HIV Treatment in Resource-limited Settings
Evolving Realities of HIV Treatment in Resource-limited Settings Papa Salif Sow MD, MSc Department of Infectious Diseases University of Dakar, Senegal Introduction: ARV access in RLS Scale-up of ART has
More informationCare of HIV Infected People
Care of HIV Infected People Patrick Ndase, MD, MPH MTN Annual Meeting Marriott Key Bridge, Arlington, VA April 21-23, 2008 Why Care for HIV infected in such a meeting? Site Core Community Why Care for
More informationTreatment Outcomes in Patients Receiving Combination Antiretroviral Therapy in Central Hospital, Benin City, Nigeria
Tropical Journal of Pharmaceutical Research, February 2010; 9 (1): 1-10 Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001 Nigeria. All rights reserved. Research Article
More informationCase Management of the TB/HIV Infected Patient
TB Nurse Case Management San Antonio, Texas December 8-10, 2009 Case Management of the TB/HIV Infected Patient Sarah Hoffman, MPH, MSN, ACRN December 9, 2009 TB/HIV: Considerations in the Care of the Coinfected
More informationPediatric HIV Update NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Pediatric HIV Update Christian B. Ramers, MD, MPH Assistant Medical Director, Family Health Centers of San Diego HIV/HCV Distance Education Specialist - NWAETC,
More informationSupplementary Methods. HIV Synthesis Transmission V1. Model details
Effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first to second line antiretroviral regimens in resource-limited settings. Supplementary
More informationKimberly Adkison, 1 Lesley Kahl, 1 Elizabeth Blair, 1 Kostas Angelis, 2 Herta Crauwels, 3 Maria Nascimento, 1 Michael Aboud 1
Pharmacokinetics of Dolutegravir and Rilpivirine After Switching to the Two-Drug Regimen From an Efavirenz- or Nevirapine- Based Antiretroviral Regimen: SWORD-1 & -2 Pooled PK Analysis Kimberly Adkison,
More informationMDR TB/HIV INTEGRATION MDR TB WORKSHOP 18 SEPTEMBER 2015
MDR TB/HIV INTEGRATION MDR TB WORKSHOP 18 SEPTEMBER 2015 HIV & MDR :Impact of early ART initiation Adjusted HR: 0.14; p = 0.042 86% reduction in mortality with ART Initiation during MDR-TB treatment 2015
More informationPaediatric ART: eligibility criteria and first line regimens. (revised) Dave le Roux 13 August 2016
Paediatric ART: eligibility criteria and first line regimens (revised) Dave le Roux 13 August 2016 Outline Eligibility criteria for starting ART Evolving evidence for earlier ART W Cape, National, WHO
More informationDr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa
Dr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa Transmitted drug resistance Resistance patterns in first-line failures in adults
More informationDeterminants of viral load rebound on HIV/ AIDS patients receiving antiretroviral therapy: results from South Africa
Shoko and Chikobvu Theoretical Biology and Medical Modelling (2018) 15:10 https://doi.org/10.1186/s12976-018-0082-0 RESEARCH Open Access Determinants of viral load rebound on HIV/ AIDS patients receiving
More informationC h a p t e r 5 5 HIV Therapy Where are We Now?
C h a p t e r 5 5 HIV Therapy Where are We Now? AK Tripathi Professor of Medicine, Physician & Haemato-Oncologist, King George s Medical College, Lucknow Introduction Human Immunodeficiency Virus type
More informationNumber of people receiving ARV therapy in developing and transitional countries by region,
Progress in numbers The last six months have seen dramatic progress toward the 3 by 5 target. Between June and, the number of people receiving antiretroviral (ARV) therapy in developing and transitional
More informationAdherence to antiretroviral drugs among AIDS patients in Sagamu, Nigeria
International Journal of Biomedical and Health Sciences 094-44/200 $12.00 + 0.00 Vol. 4, No. 2, June 0, 200 200 African Studies on Population and Health Printed in Nigeria http://www.asopah.org IJBHS 20009/4201
More information1. Introduction. Wendwesen Abayneh 1, Nigusse Obse 2, Tamene Naba 3
International Journal of HIV/AIDS Prevention, Education and Behavioural Science 2017; 3(3): 22-27 http://www.sciencepublishinggroup.com/j/ijhpebs doi: 10.11648/j.ijhpebs.20170303.11 Factors Associated
More informationSupplementary Appendix
Supplementary Appendix This supplementary Appendix accompanies the article Cost-Effectiveness of HIV Monitoring Strategies in Resource-Limited Settings (Archives of Internal Medicine, September 22, 2008),
More informationTB/HIV CO-INFECTION ADULT & CHILDREN (INCLUDING INH PROPHYLAXIS) ART Treatment Guideline Training 31 st January to 4 th February, 2011
TB/HIV CO-INFECTION ADULT & CHILDREN (INCLUDING INH PROPHYLAXIS) ART Treatment Guideline Training 31 st January to 4 th February, 2011 OUTLINE Background Global Incidence The Problem" The 3 I s Drug Resistant
More informationEfavirenz, stavudine and lamivudine
efavirenz, stavudine, lamivudine: 1 efavirenz, stavudine and lamivudine First line ART treatment for HIV infection Efavirenz, stavudine and lamivudine efavirenz, stavudine, lamivudine: 2 Slide 1 Information
More informationFactors associated with adherence of highly active antiretroviral therapy among adult HIV/AIDS patients in Mekelle Hospital Northern Ethiopia
Science Journal of Public Health 2014; 2(4): 367-372 Published online July 30, 2014 (http://www.sciencepublishinggroup.com/j/sjph) doi: 10.11648/j.sjph.20140204.30 ISSN: 2328-7942 (Print); ISSN: 2328-7950
More informationElimination of mother to child transmission of HIV: is the end really in sight? Lisa L. Abuogi, MD University of Colorado, Denver Dec 3, 2014
Elimination of mother to child transmission of HIV: is the end really in sight? Lisa L. Abuogi, MD University of Colorado, Denver Dec 3, 2014 Outline Background History of prevention of mother to child
More informationThe next generation of ART regimens
The next generation of ART regimens By Gary Maartens Presented by Dirk Hagemeister Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Current state
More informationEXPLORING THE IMPACT OF SEX DISCREPANCIES IN HIV TREATMENT AND CURE
EXPLORING THE IMPACT OF SEX DISCREPANCIES IN HIV TREATMENT AND CURE CECILE DELILLE LAHIRI, M.D, M.SC ASSISTANT PROFESSOR DIVISION OF INFECTIOUS DISEASES MAY 18, 2016 OUTLINE Describe discrepancy between
More informationHIV and contraception the latest recommendations
1 8-11 June 2015, Chiang-Mai HIV and contraception the latest recommendations Mary Lyn Gaffield, Sharon Phillips, Rachel Baggaley, Petrus Steyn, and Marleen Temmerman 2 Medical eligibility criteria for
More informationCLAUDINE HENNESSEY & THEUNIS HURTER
HIV/AIDS/TB CLAUDINE HENNESSEY & THEUNIS HURTER KEY TERMS Do these sound familiar? What strange terms do you hear in the clinics? Any others to add?? HIV AIDS Viral Load & suppression CD4 count Regimen
More informationART for HIV Prevention:
ART for HIV Prevention: KENNETH H. MAYER, M.D. Brown University/The Fenway Institute August 22, 2009 APPROACHES TO PREVENT HIV TRANSMISSION DECREASE SOURCE OF INFECTION Barrier Protection Treat STI Antiretroviral
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationPRINCIPLES and TRENDS in MANAGEMENT of HIV DISEASE: PROBLEMS OF DRUG RESISTANCE in VIRUSES of DIFFERENT SUBTYPES
PRINCIPLES and TRENDS in MANAGEMENT of HIV DISEASE: PROBLEMS OF DRUG RESISTANCE in VIRUSES of DIFFERENT SUBTYPES Mark A. Wainberg McGill University AIDS Centre Jewish General Hospital Montreal, Quebec,
More informationTenofovir disoproxil STADA 245 mg film-coated tablets , Version 1.2 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN
Tenofovir disoproxil STADA 245 mg film-coated tablets 9.3.2016, Version 1.2 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology HIV-1 infection
More information43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) A Cutrell, J Hernandez, M Edwards, J Fleming, W Powell, T Scott
43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Poster H-2013 Clinical Risk Factors for Hypersensitivity Reactions to Abacavir: Retrospective Analysis of Over 8,000 Subjects
More information